Cargando…

P1096: TREATMENT PATTERNS AND OUTCOMES IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA

Detalles Bibliográficos
Autores principales:	Bock, A., Poonsombudlert, K., Larson, M., Gile, J., Tawfiq, R., Maliske, S., Maurer, M., Cerhan, J., Andrade-gonzalez, X., Saliba, A., Paludo, J., Inwards, D., Ansell, S., Witzig, T., Habermann, T., Link, B., Ayyappan, S., Nowakowski, G., Farooq, U., Wang, Y.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429266/ http://dx.doi.org/10.1097/01.HS9.0000847252.52414.37

Ejemplares similares

Evolving treatment patterns and improved outcomes in relapsed/refractory mantle cell lymphoma: a prospective cohort study
por: Bock, Allison M., et al.
Publicado: (2023)

Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes
por: Castellino, Alessia, et al.
Publicado: (2022)

Clinical characteristics and outcomes of primary versus secondary gastrointestinal mantle cell lymphoma
por: Castellino, Alessia, et al.
Publicado: (2021)

Outcomes of Patients With Classic Hodgkin Lymphoma Who Relapsed After Autologous Stem Cell Transplant
por: Tun, Aung M., et al.
Publicado: (2023)

P1152: DEPTH OF METABOLIC RESPONSE AT INTERIM PET AND SURVIVAL OUTCOMES AMONG PATIENTS WITH PRIMARY REFRACTORY OR EARLY RELAPSING DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
por: Bock, Allison, et al.
Publicado: (2023)

P1168: CHARACTERISTICS PREDICTIVE OF PROGRESSION DURING FRONTLINE TREATMENT IN AGGRESSIVE B-CELL LYMPHOMAS
por: Bock, A., et al.
Publicado: (2022)

Cell of origin is not associated with outcomes of relapsed or refractory diffuse large B cell lymphoma
por: Desai, Sanjal H., et al.
Publicado: (2022)

Vitamin D insufficiency is associated with an increased risk of early clinical failure in follicular lymphoma
por: Tracy, S I, et al.
Publicado: (2017)

High rate of event-free survival at 24 months with everolimus/RCHOP for untreated diffuse large B-cell lymphoma: updated results from NCCTG N1085 (Alliance)
por: Witzig, T E, et al.
Publicado: (2017)

The significance of gradient expression of chromosome region maintenance protein 1 in large cell lymphoma
por: Abeykoon, Jithma P., et al.
Publicado: (2021)

Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era
por: Arushi Khurana, et al.
Publicado: (2021)

1096. Reducing Unnecessary Postoperative Antibiotic Prophylaxis
por: Metjian, Talene A, et al.
Publicado: (2019)

1096 Impact of Universal Pneumococal Vaccination in Children in Argentina
por: López, Eduardo L., et al.
Publicado: (2014)

1096. Evaluation of Vancomycin Pharmacokinetics in Intravenous Drug Users
por: Weihs, Sayo, et al.
Publicado: (2021)

History of autoimmune conditions and lymphoma prognosis
por: Kleinstern, Geffen, et al.
Publicado: (2018)

Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression
por: Tracy, Sean I., et al.
Publicado: (2018)

PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts
por: Desai, Sanjal H., et al.
Publicado: (2022)

Causes of death in low-grade B-cell lymphomas in the rituximab era: a prospective cohort study
por: Tun, Aung M., et al.
Publicado: (2022)

P1145: OUTCOMES AND TREATMENT PATTERNS AFTER FIRST RELAPSE IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA
por: Tawfiq, R., et al.
Publicado: (2022)

Peripheral blood absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles predicts clinical outcomes in classical Hodgkin lymphoma
por: Porrata, L F, et al.
Publicado: (2013)

The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas
por: Briski, R, et al.
Publicado: (2014)

Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients
por: Krull, Jordan E., et al.
Publicado: (2020)

Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements
por: McPhail, Ellen D., et al.
Publicado: (2018)

The medical resources and practice of the crusader states in Syria and Palestine 1096-1193.
por: Woodings, A F
Publicado: (1971)

Salient Features of the Maasai Foot: Analysis of 1,096 Maasai Subjects
por: Choi, Jun Young, et al.
Publicado: (2014)

Validation of a vitamin D replacement strategy in vitamin D-insufficient patients with lymphoma or chronic lymphocytic leukemia
por: Sfeir, J G, et al.
Publicado: (2017)

Whole-exome analysis reveals novel somatic genomic alterations associated with cell of origin in diffuse large B-cell lymphoma
por: Manso, B A, et al.
Publicado: (2017)

Whole-exome analysis reveals novel somatic genomic alterations associated with outcome in immunochemotherapy-treated diffuse large B-cell lymphoma
por: Novak, A J, et al.
Publicado: (2015)

Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphoma
por: Villa, Diego, et al.
Publicado: (2023)

1096. Effect of Diarrheal Illness During Pregnancy on Adverse Birth Outcomes in Nepal
por: Newman, Kira, et al.
Publicado: (2018)

Outcomes in 1096 patients with severe thrombotic thrombocytopenic purpura before the Caplacizumab era
por: Van de Louw, Andry, et al.
Publicado: (2021)

Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma
por: Epperla, Narendranath, et al.
Publicado: (2022)

Targeting of Inflammatory Pathways with R2CHOP in High-Risk DLBCL
por: Hartert, Keenan T., et al.
Publicado: (2020)

Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study
por: Desai, Sanjal H., et al.
Publicado: (2021)

Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma
por: Wang, Yucai, et al.
Publicado: (2019)

Increasing tissue requirements in lymphoma trials may exclude patients with high-risk disease or worse prognosis
por: Desai, Sanjal H., et al.
Publicado: (2022)

Bortezomib in mantle cell lymphoma: comparative therapeutic outcomes
por: Vallumsetla, Nishanth, et al.
Publicado: (2015)

Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study
por: Zinzani, P. L., et al.
Publicado: (2013)

SG-APSIC1096: Changes in resistance patterns of “ESKAPE” pathogens to azithromincin and levofloxacin in Yogyakarta
por: Asdie, Rizka, et al.
Publicado: (2023)

Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression
por: Bennani, N Nora, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ooh656h16ubrmdp5q528b2a9as